Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ARCT Arcturus Therapeutics Holdings Inc
- Stocks
- Healthcare
- NASDAQ: ARCT
Price (delayed)
$10.98
Market cap
$297.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3
Enterprise value
$30.75M
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™
Highlights
Arcturus Therapeutics Holdings's debt has decreased by 3.8% QoQ and by 3.5% YoY
The net income has dropped by 172% year-on-year and by 29% since the previous quarter
The company's EPS has shrunk by 168% YoY and by 28% QoQ
Key stats
What are the main financial stats of ARCT
Market
Valuations
Earnings
Shares outstanding
27.12M
Market cap
$297.78M
Enterprise value
$30.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.23
Price to sales (P/S)
1.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.2
Revenue
$152.31M
Gross profit
$152.31M
Operating income
-$95.67M
Net income
-$80.94M
EBIT
-$96.14M
EBITDA
-$92.6M
Free cash flow
-$60.4M
Per share
Balance sheet
Liquidity
EPS
-$3
EPS diluted
-$3
Free cash flow per share
-$2.24
Book value per share
$8.9
Revenue per share
$5.64
TBVPS
$12.74
Total assets
$344.07M
Total liabilities
$103.09M
Debt
$25M
Equity
$240.98M
Working capital
$240.49M
Debt to equity
0.1
Current ratio
4.67
Quick ratio
4.52
Net debt/EBITDA
2.88
Margins
Efficiency
Dividend
EBITDA margin
-60.8%
Gross margin
100%
Net margin
-53.1%
Operating margin
-62.8%
Return on assets
-21.3%
Return on equity
-31.6%
Return on invested capital
-899.5%
Return on capital employed
-34.5%
Return on sales
-63.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARCT stock price
How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-3.51%
1 week
-14.42%
1 month
11.81%
1 year
-59.01%
YTD
-35.3%
QTD
3.68%
Financial performance
How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$152.31M
Gross profit
$152.31M
Operating income
-$95.67M
Net income
-$80.94M
Gross margin
100%
Net margin
-53.1%
Arcturus Therapeutics Holdings's net margin has shrunk by 198% YoY and by 36% QoQ
The net income has dropped by 172% year-on-year and by 29% since the previous quarter
Arcturus Therapeutics Holdings's operating margin has decreased by 34% YoY and by 25% QoQ
Arcturus Therapeutics Holdings's operating income has decreased by 22% YoY and by 19% QoQ
Price vs fundamentals
How does ARCT's price correlate with its fundamentals
Growth
What is Arcturus Therapeutics Holdings's growth rate over time
Valuation
What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
1.23
P/S
1.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.2
The company's EPS has shrunk by 168% YoY and by 28% QoQ
ARCT's P/B is 63% lower than its 5-year quarterly average of 3.3 and 53% lower than its last 4 quarters average of 2.6
ARCT's equity is down by 13% year-on-year and by 8% since the previous quarter
ARCT's price to sales (P/S) is 95% lower than its 5-year quarterly average of 42.5 and 58% lower than its last 4 quarters average of 4.6
The revenue has declined by 9% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is Arcturus Therapeutics Holdings business performance
The company's return on sales has shrunk by 136% YoY and by 28% QoQ
Arcturus Therapeutics Holdings's ROIC has plunged by 64% from the previous quarter
The ROA has decreased by 37% QoQ
The company's return on equity fell by 34% QoQ
Dividends
What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARCT.
Financial health
How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total liabilities has decreased by 32% YoY and by 5% QoQ
Arcturus Therapeutics Holdings's total assets has decreased by 20% YoY and by 7% QoQ
Arcturus Therapeutics Holdings's debt is 90% lower than its equity
ARCT's equity is down by 13% year-on-year and by 8% since the previous quarter
The debt to equity has increased by 11% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.